Supaglutide
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants
Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 1 · Completed · Enrollment 48
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 0.15mg Supaglutide or placebo | n/r | n/r | n/r | n/r |
| 0.375mg Supaglutide or placebo | n/r | n/r | n/r | n/r |
| 0.75mg Supaglutide or placebo | n/r | n/r | n/r | n/r |
| 1.5mg Supaglutide or placebo | n/r | n/r | n/r | n/r |
| 3.0mg Supaglutide or placebo | n/r | n/r | n/r | n/r |
Not shown
- 0.15mg Supaglutide or placebo: endpoint not reported
- 0.375mg Supaglutide or placebo: endpoint not reported
- 0.75mg Supaglutide or placebo: endpoint not reported
- 1.5mg Supaglutide or placebo: endpoint not reported
- 3.0mg Supaglutide or placebo: endpoint not reported